AZD0466 Nimble Trial Screening in Australia

This morning I did a google search of AZD0466 Nimble Trial for an update and the following information came up first




NIMBLE-AZD0466 : A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

Male Or
Female
StatusRecruiting
Systemic
Therapy Trial
PhaseOne/Two
18-130Age18-130
Blood
Cancers
Trial OverviewRead More

This phase I/II study is evaluating how safe, tolerable and effective a new targeted therapy (AZD0466) is in people with blood cancers, and to also assess the interaction it has with an antifungal drug voriconazole.

This trial is treating patients with advanced blood cancers.
This is a systemic therapy trial.
You may be able to join this trial if:

• You are able to swallow medication by mouth.

You may be excluded from this trial if:

• You have a certain disease or psychological condition.
• You have been diagnosed with a prior or secondary type of cancer.
• You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical SummaryRead More

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

• NCT04865419
• D8241C00001

Scientific Title

A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
Commercial Sponsor

AstraZeneca
Summary

This study consists of 2 individual modules: Module 1 (AZD0466 monotherapy), and Module 2 (Drug-Drug Interaction study of AZD0466 with voriconazole). In Module 1, AZD0466 monotherapy will include 2 parts- Part A (dose escalation) cohorts and Part B (dose expansion) cohorts. Initiation of Part B will depend on the evaluation of safety, tolerability and pharmacokinetics in Part A. AZD0466 will be administered via intravenous infusion (IV). In Module 2, participants may receive AZD0466 (administered via IV) in combination with or without voriconazole (administered orally).
Recruiting Hospitals



Alfred Hospital, Malignant Haematology & Stem Cell Transplantation Service
Prahran
Ms Nola Kennedy
[email protected]
03 9076 2217
PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Jessica Ahern
[email protected]
* Incorporates Medical Oncology from Peter Mac, Royal Melbourne and Royal Women's Hospital